Trial Profile

Study of Tilsotolimod in Combination With Nivolumab and Ipilimumab for the Treatment of Solid Tumors

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 09 Feb 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Tilsotolimod (Primary)
Indications Colorectal cancer; Head and neck cancer; Solid tumours; Squamous cell cancer
Focus Registrational; Therapeutic Use
Acronyms ILLUMINATE-206
Sponsors Aceragen; Idera Pharmaceuticals

Most Recent Events

17 Jan 2023 According to an Aceragen media release, Idera Pharmaceuticals has changed its name to Aceragen.
08 Nov 2021 According to an Idera Pharmaceuticals media release, the company expect to share data from this trial by the end of the year.
09 Aug 2021 Status changed from recruiting to active, no longer recruiting, according to an Idera Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com